Deep brain stimulation is a recognized and effective treatment for several movement disorders. Nevertheless, the efficacy of this intervention on abnormal movements secondary to structural brain pathologies is less consistent. In this report, we describe a case of hemiballism-hemichorea due to a peripartum ischemic stroke-treated with deep brain stimulation of the globus pallidus internus. Patient observed marked improvement in her symptoms at long-term follow-up. Neurophysiologic data revealed lower globus pallidus internus firing rates compared to other hyperkinetic disorders. Pallidal deep brain stimulation is a plausible option for medically refractory hemiballism-hemichorea and cumulative data from multiple centers may be used to fully evaluate its efficacy.
Introduction
Deep brain stimulation (DBS) is an established therapy for treating a variety of medication-refractory movement disorders including Parkinson disease (PD), dystonia, and essential tremor (Perlmutter & Mink, 2006) . 17 However, the therapeutic effect of DBS on abnormal movements secondary to structural brain pathologies have demonstrated less consistent or even disappointing results. [1] [2] [3] New-onset movement disorders occurring after a primary stroke or as a complication of neurosurgery are rare, but dystonia, hemichorea (HC), and hemiballismus (HB) have been reported after vascular events affecting the striatum, putamen, thalamus, or subthalamic nucleus (STN). 4 Patients with chorea exhibit involuntary, continual, and irregular movements that flow randomly from one body part to another, whereas ballism is a form of high-amplitude flinging resulting from chorea involving proximal limb muscles.
Abnormal movements following a stroke can occur immediately or can be delayed and progressive. HC-HB arising after stroke may improve with medical therapy but in certain circumstances, neurosurgical intervention may be appropriate particularly for refractory symptoms. Despite the well-established benefit of pallidal DBS for primary dystonia, poststroke dystonia has remained particularly difficult to treat with DBS. 5 On the other hand, a limited number of case reports suggest the potential for DBS as a treatment for poststroke HC-HB. To the best of our knowledge, however, of these four published cases of pallidal DBS for HC-HB secondary to stroke, long-term clinical data is lacking. [6] [7] [8] [9] In this report, we describe a novel case of HC-HB that developed secondary to a peripartum ischemic stroke. The patient was successfully treated with DBS of the globus pallidus internus (GPi). We provide details of intraoperative neurophysiology and report on clinical outcomes at 28 months' follow-up. Given the novelty of this specific application of DBS, we present a brief review of established pallidal microelectrode neurophysiology and compare it to the intraoperative GPi firing rates observed in this case.
Patients and Methods
Patient is a 53-year-old woman presenting with insidious onset, progressive, left arm abnormal involuntary movements starting in her 30s after she suffered peripartum right thalamic cerebral infarction (Fig. 1) . New motor symptoms appeared approximately 6 months poststroke after resolution of left hemi-body numbness and weakness. Her symptoms progressed over the following years leading to severe, unremitting, large amplitude, irregular, random movements in her left arm causing marked functional impairments consistent with HB. She had no meaningful use of her left arm. There was no involvement of ipsilateral leg or face and a variety of medications failed to provide benefit including dopamine receptor blocking agents, levodopa, benztropine, trihexiphenidyl, valproic acid, benzodiazepines, and tetrabenazine. Because of the severe disability related to her symptoms, she had placement of unilateral right GPi DBS. The patient was not taking any neurological or psychiatric medications during surgery and an awake procedure was conducted to facilitate microelectrode recordings. Motor improvement was gradual after monthly programming sessions over the first 6 months. At last follow-up at 28 months postoperative, she displayed marked improvement in her symptoms with almost complete resolution of HB (Video S1). Therapeutic stimulation parameters were as follows: Case positive, contact 0 negative, amplitude of 3.0 V, pulse width of 90 lsec, and frequency of 130 Hz. Reversible side effects were encountered at higher levels of stimulation, namely dysarthria and tonic arm contractions.
Neurophysiology
Single-unit activity recordings were obtained from this patient using microelectrodes during surgery in the GPi and globus pallidus externus (GPe) based on characteristic firing patterns. A total of 22 and seven cells were recorded from the GPi and GPe, respectively. The mean GPi and GPe firing rates for our HC-HB patient (shown as mean AE SEM) were 16.00 AE 3.18 and 32.00 AE 10.60 Hz, respectively. For comparison, Table 1 provides an overview of prior work characterizing firing rates of GPi and GPe neurons in patients with PD, dystonia, Huntington's disease (HD), and HB.
Discussion
This is the first description of medication-refractory HC-HB secondary to thalamic peripartum stroke treated with GPi DBS. In addition to this case, a limited number of reports have demonstrated the feasibility of pallidal DBS for poststroke HC-HB. Hasegawa et al. 9 were the first to report a case of a primary hemorrhagic subthalamic stroke-induced HB treated with GPi DBS. The patient experienced rapid symptomatic improvement that persisted at 15-months' follow-up. Capelle et al. 7 described the case of a patient developing HC-HB after resection of a craniopharyngioma that was subsequently treated with combined GPi and thalamic DBS. They found that stimulation to either target suppressed HC-HB movements, but that therapeutic thalamic stimulation required less voltage. Both Oyama et al. 6 and Pabaney et al. 8 have reported patients requiring further treatment for medication-refractory HC-HB developed as a complication of STN DBS for PD. In both cases, highfrequency GPi stimulation proved clinically efficacious for HC-HB. Similar to the above reports, in this patient we observed suppression of HC-HB after GPi DBS therapy. Notably, in this patient, symptomatic improvement remained stable at the last known follow-up of 28 months after DBS. In addition, there were no adverse outcomes associated with DBS therapy in this patient. Given the rarity of these cases and mixed treatment strategies, no two cases in the literature are alike. However, there are now multiple reports suggesting the potential promise of GPi DBS for HC-HB secondary to certain basal ganglia lesions. Importantly, benefit in our patient was achieved despite a very long latency period from onset of symptoms to surgery of almost three decades.
While both dystonia and HB are recognized complications of cerebrovascular injuries to the basal ganglia, the response to DBS in patients with secondary dystonia is not nearly as consistent, nor robust, as that of patients with primary dystonia. 2, 5 This pattern also persists when examining poststroke dystonia. 1, 5, 7 In contrast, the application of GPi DBS for poststroke HB has been demonstrated successfully across different specific clinical scenarios. The explanation for this observed discrepancy in response to DBS in poststroke dystonia and HB is not known. We believe one important feature that distinguishes these two conditions is the extent of damage incurred due to the stroke and therefore the remaining intact striatopallidal network. 10 In a series of 27 patients with HB secondary to a stroke, 77% were found to be due to lacunar strokes. 4 The average latency period for manifestation of HC-HB is 4 days poststroke. 11 While poststroke HB is usually the manifestation of a strategic infarct in the striatum, poststroke dystonia more frequently arises from a larger vascular insult and presents itself months to years after the sentinel event. In fact, poststroke dystonia patients that do respond favorably to GPi DBS tend to have structurally normal MRIs, while those that do not have basal ganglia abnormalities. 5 Thus, relative preservation of basal ganglia structures may be an important predictor of response to GPi DBS for poststroke HB and dystonia. This is an area that requires further investigation.
Neurophysiology
Additionally, we measured pallidal firing frequencies during intraoperative microelectrode targeting in this patient. A comparison between these values and that of patients with PD, dystonia, HD, and other reports of HC-HB (Table 1 ) revealed important observations. Specifically, our patient had a GPi mean firing rate of 16.00 AE 3.18 Hz, which is considerably lower than that found in the GPi in other diseases. This is consistent with prior work that has statistically compared groups of GPi cells in patients with HB and PD. 12 One study found similar firing rates in the GPi between patients with HB and dystonia, both of which were lower than GPi firing rates in PD. 13 In contrast to our results and those of others, Tang et al. 14 found similar GPi firing rates in patients with PD and HD displaying levodopa induced dyskinesia and chorea. We found mean GPe firing rates in our patient to be 32.00 AE 10.60 Hz, which were generally higher and not all that different from previously established GPe firing rates in PD and dystonia. 13, 15 Interestingly, in one case report, the mean firing rate of GPe neurons in a patient with HB was found to be 13.0 AE 1.8, which is lower than other reports. Our values more closely align with a separate HC-HB case report that found a mean GPe firing rate of 41 Hz. 7 Although more research is needed, overall it appears that GPi firing rates are generally lower in hyperkinetic disorders, whereas GPe firing rates currently show unclear relationships to different movement disorders. However, the data are limited to single case reports and other factors might contribute to changes in firing rates including sparse sampling or the presence of resting tremor in PD patients modulating sensory feedback and increasing firing rates compared to other conditions. Nevertheless, these observations can be enlightening in the context of the canonical basal ganglia motor loop. It has been previously postulated that hyperkinetic disorders resulting from basal ganglia lesions can occur due to a reduced influence of the indirect pathway on basal ganglia output nuclei. Specifically, low levels of excitatory output from the STN can lead to an underactivated GPi, thereby lessening inhibition on the motor thalamus. Relative to the firing rate of GPi neurons in hypokinetic disorders, the lower firing rates observed in hyperkinetic disorders is therefore in support of this hypothesis.
Conclusion
Given the low incidence of poststroke HB (0.5%, prevalence 1%), it is unclear whether it is a disease phenomenon that more commonly progresses toward remission, persists unchanged, or exacerbates with time.
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Although definitive evidence is lacking, with this account representing the fifth of its kind, the relative safety and reversibility of GPi DBS makes it a valuable proposition for those suffering from the disease. As GPi DBS gains traction as a feasible option for medically refractory HB, aggregate data amassed from multiple DBS centers may be used to fully evaluate its efficacy. For now, we must make use of case reports depicting both treatment success and treatment failures for poststroke HB. Additionally, the reporting of intraoperative microelectrode recording data may further improve patient selection and understanding of this modality's success.
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